Last reviewed · How we verify
Intravenous Infusion of Aclasta®
Intravenous Infusion of Aclasta® is a Bisphosphonate Small molecule drug developed by AUVA Traumazentrum Vienna Site UKH Meidling. It is currently in Phase 2 development for Treatment of osteoporosis in postmenopausal women, Treatment of bone metastases in patients with breast cancer or multiple myeloma.
Bisphosphonate that inhibits osteoclast-mediated bone resorption
Bisphosphonate that inhibits osteoclast-mediated bone resorption Used for Treatment of osteoporosis in postmenopausal women, Treatment of bone metastases in patients with breast cancer or multiple myeloma.
At a glance
| Generic name | Intravenous Infusion of Aclasta® |
|---|---|
| Sponsor | AUVA Traumazentrum Vienna Site UKH Meidling |
| Drug class | Bisphosphonate |
| Target | Farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Aclasta, also known as zoledronic acid, is a bisphosphonate that works by inhibiting the mevalonate pathway in osteoclasts, leading to a decrease in bone resorption.
Approved indications
- Treatment of osteoporosis in postmenopausal women
- Treatment of bone metastases in patients with breast cancer or multiple myeloma
Common side effects
- Fever
- Nausea
- Bone pain
Key clinical trials
- Influence of an Anti-osteoporotic Drug on Healing After Surgical Repair of Chronic Rotator Cuff Lesions of the Shoulder (PHASE2)
- Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy (PHASE3)
- Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma (PHASE3)
- Re-treatment of Participants With Paget's Disease Using Zoledronic Acid (PHASE4)
- Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants (PHASE4)
- Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis (PHASE4)
- Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer (NA)
- A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous Infusion of Aclasta® CI brief — competitive landscape report
- Intravenous Infusion of Aclasta® updates RSS · CI watch RSS
- AUVA Traumazentrum Vienna Site UKH Meidling portfolio CI
Frequently asked questions about Intravenous Infusion of Aclasta®
What is Intravenous Infusion of Aclasta®?
How does Intravenous Infusion of Aclasta® work?
What is Intravenous Infusion of Aclasta® used for?
Who makes Intravenous Infusion of Aclasta®?
What drug class is Intravenous Infusion of Aclasta® in?
What development phase is Intravenous Infusion of Aclasta® in?
What are the side effects of Intravenous Infusion of Aclasta®?
What does Intravenous Infusion of Aclasta® target?
Related
- Drug class: All Bisphosphonate drugs
- Target: All drugs targeting Farnesyl pyrophosphate synthase
- Manufacturer: AUVA Traumazentrum Vienna Site UKH Meidling — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of osteoporosis in postmenopausal women
- Indication: Drugs for Treatment of bone metastases in patients with breast cancer or multiple myeloma
- Compare: Intravenous Infusion of Aclasta® vs similar drugs
- Pricing: Intravenous Infusion of Aclasta® cost, discount & access